Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

At ESMO, AZ and Daiichi Sankyo also reported encouraging new results from the DESTINY-Lung01 study in HER2-positive non-small cell lung cancer (NSCLC), including an overall response rate of 55% ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...